课题基金 / 基金详情

Dopamine Transporter--structure/function Studies Of Tran

Dopamine Transporter--structure/function Studies Of Tran
多巴胺转运蛋白--反式结构/功能研究
批准号:
6827255
负责人:
George Richard Uhl
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:

项目摘要

项目成果

George Richard Uhl的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The dopamine transporter (DAT) has been a principal brain receptor site that has been correlated with the rewarding and euphoric properties of cocaine. MNB scientists have found that deletion of DAT and SERT are required to eliminate cocaine conditioned place preferences in mice. DAT is required for the actions of each of the current dopamine-selective toxins that produce the best models of Parkinson's disease. Analyses of DAT structure- function relationships, and their relationships with SERT, continued during this year with further characterization of the roles of selected amino acid sidechains in transporter functions. These studies have focused on single- and multiple-domaine amino acid changes of interest in the rat dopamine transporter and on characterization of the amino acid changes produced by human allelic variants of the DAT sequence identified in other studies reported during this year. Studies reported during this year document surprisingly large effects of serine and threonine substitutions on the DAT activity effects of drugs that activate or inhibit PKC, MAP, MEK kinase, and IP3 kinase pathways. Studies completed during this year have also identified a large effect of coexpression of the PKC-dependent PP1 inhibitor, KEPI (identified in this laboratory as a morphine-upregulated gene)on the function of coexpressed DAT. Studies reported during this year also document surprisingly-selective effects of DAT point mutations on efflux of dopamine from DAT-expreessing cells. These insights should continue to help in identification of structure- function features of small molecule compounds possibly active in vivo as cocaine antagonists, structure-function relationships relevant to DAT regulation, and human individual differences in DAT pharmacology.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PTPRD phosphatase inhibitors for stimulant use disorders
  • 批准号:
    10710969
  • 项目类别:
  • 资助金额:
    $38.63万
  • 财政年份:
    2022
  • 负责人:
    George Richard Uhl
  • 依托单位:
PTPRD phosphatase inhibitors for stimulant use disorders
  • 批准号:
    10653070
  • 项目类别:
  • 资助金额:
    $139.15万
  • 财政年份:
    2022
  • 负责人:
    George Richard Uhl
  • 依托单位:
PTPRD phosphatase inhibitors for stimulant use disorders
  • 批准号:
    10457132
  • 项目类别:
  • 资助金额:
    $145.39万
  • 财政年份:
    2022
  • 负责人:
    George Richard Uhl
  • 依托单位:
PTPRD ligands for stimulant and opiate use disorders
海外基金